Transmission and Non-transmission of Melanoma From Deceased Solid Organ Donors to Transplant Recipients: Risks and Missed Opportunities.
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
29 Feb 2024
29 Feb 2024
Historique:
medline:
29
2
2024
pubmed:
29
2
2024
entrez:
29
2
2024
Statut:
aheadofprint
Résumé
Biovigilance concerns are in tension with the need to increase organ donation. Cancer transmission risk from donor to recipient may be overestimated, as non-transmission events are rarely reported. We sought to estimate melanoma transmission risk in deceased organ donation and identify missed opportunities for donation in an Australian cohort with high melanoma prevalence. We used a population-based approach and linked deceased organ donors, transplant recipients, and potential donors forgone, 2010-2018, with the Central Cancer Registry (CCR), 1976-2018. We identified melanomas using ICD-O-3 classification, assessed the probability of transmission, and compared suspected melanoma history in potential donors forgone with melanoma notifications in the CCR. There were 9 of 993 donors with melanoma in CCR; 4 in situ low-risk and 5 invasive high-to-unacceptable risk. Four were unrecognized before donation. Of 16 transplant recipients at risk, we found 0 of 14 transmission events (2 recipients had insufficient follow-up). Of 35 of 3588 potential donors forgone for melanoma risk alone, 17 were otherwise suitable for donation; 6 of 35 had no melanoma in CCR, 2 of 35 had in situ melanomas and 9 of 35 had thin invasive melanomas (localized, ≤0.8 mm thickness). Our findings contribute to current evidence that suggests donors with melanomas of low metastatic potential may provide an opportunity to safely increase organ donation and so access to transplantation.
Sections du résumé
BACKGROUND
BACKGROUND
Biovigilance concerns are in tension with the need to increase organ donation. Cancer transmission risk from donor to recipient may be overestimated, as non-transmission events are rarely reported. We sought to estimate melanoma transmission risk in deceased organ donation and identify missed opportunities for donation in an Australian cohort with high melanoma prevalence.
METHODS
METHODS
We used a population-based approach and linked deceased organ donors, transplant recipients, and potential donors forgone, 2010-2018, with the Central Cancer Registry (CCR), 1976-2018. We identified melanomas using ICD-O-3 classification, assessed the probability of transmission, and compared suspected melanoma history in potential donors forgone with melanoma notifications in the CCR.
RESULTS
RESULTS
There were 9 of 993 donors with melanoma in CCR; 4 in situ low-risk and 5 invasive high-to-unacceptable risk. Four were unrecognized before donation. Of 16 transplant recipients at risk, we found 0 of 14 transmission events (2 recipients had insufficient follow-up). Of 35 of 3588 potential donors forgone for melanoma risk alone, 17 were otherwise suitable for donation; 6 of 35 had no melanoma in CCR, 2 of 35 had in situ melanomas and 9 of 35 had thin invasive melanomas (localized, ≤0.8 mm thickness).
CONCLUSIONS
CONCLUSIONS
Our findings contribute to current evidence that suggests donors with melanomas of low metastatic potential may provide an opportunity to safely increase organ donation and so access to transplantation.
Identifiants
pubmed: 38419163
doi: 10.1097/TP.0000000000004961
pii: 00007890-990000000-00676
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
World Health O. Ethics, access and safety in tissue and organ transplantation: issues of global concern, Madrid, Spain, 6-9 October 2003: report. In. Geneva: World Health Organization; 2004.
Advisory Committee on the Safety of Blood TaOS. Transplantation of organs from deceased donors with cancer or a history of cancer. Department of Health and Social Care, Vol 2. London, UK 2020.
Mahíllo B, Martín S, Molano E, et al. Malignancies in deceased organ donors: the Spanish experience. Transplantation. 2022;106:1814–1823.
Nalesnik MA. Donor cancer transmission: focusing on the evidence. Transplantation. 2022;106:1728–1729.
Desai R, Collett D, Watson CJ, et al. Estimated risk of cancer transmission from organ donor to graft recipient in a national transplantation registry. Br J Surg. 2014;101:768–774.
Organ Procurement and Transplantation Network. OPTN Policies. US Department of Health and Human Services, 2023.
The Transplantation Society of Australia and New Zealand. Clinical guidelines for organ transplantation from deceased donors. Canberra, Australia: The Transplantation Society of Australia and New Zealand; 2022.
Kaul DR, Vece G, Blumberg E, et al. Ten years of donor-derived disease: A report of the disease transmission advisory committee. Am J Transplant. 2021;21:689–702.
Eccher A, Girolami I, Marletta S, et al. Donor-transmitted cancers in transplanted livers: analysis of clinical outcomes. Liver Transpl. 2021;27:55–66.
Eccher A, Girolami I, Motter JD, et al. Donor-transmitted cancer in kidney transplant recipients: a systematic review. J Nephrol. 2020;33:1321–1332.
Zwald FO, Christenson LJ, Billingsley EM, et al.; Melanoma Working Group of The International Transplant Skin Cancer Collaborative and Skin Care in Organ Transplant Patients, Europe. Melanoma in solid organ transplant recipients. Am J Transplant. 2010;10:1297–1304.
Abdullayeva L. Donor-transmitted melanoma: is it still bothering us? Curr Treat Options Oncol. 2020;21:38.
Greenhall GHB, Ibrahim M, Dutta U, et al. Donor-transmitted cancer in orthotopic solid organ transplant recipients: a systematic review. Transpl Int. 2021;35:10092.
Ison MG, Nalesnik MA. An update on donor-derived disease transmission in organ transplantation. Am J Transplant. 2011;11:1123–1130.
Green M, Covington S, Taranto S, et al. Donor-derived transmission events in 2013: a report of the Organ Procurement Transplant Network Ad Hoc Disease Transmission Advisory Committee. Transplantation. 2015;99:282–287.
Kauffman HM, McBride MA, Delmonico FL. First report of the United Network for Organ Sharing Transplant Tumor Registry: donors with a history of cancer. Transplantation. 2000;70:1747–1751.
Lo SN, Ma J, Scolyer RA, et al. Improved risk prediction calculator for sentinel node positivity in patients with melanoma: The Melanoma Institute Australia Nomogram. J Clin Oncol. 2020;38:2719–2727.
Williams GJ, Webster AC, Thompson JF. Organ transplantation and outcomes in patients with a past history of melanoma: a systematic review and meta-analysis. Clin Transplant. 2021;35:e14287.
Al-Adra DP, Hammel L, Roberts J, et al. Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: a consensus expert opinion statement. Am J Transplant. 2021;21:475–483.
Arnold M, Singh D, Laversanne M, et al. Global burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatology. 2022;158:495–503.
Ossowski L, Aguirre-Ghiso JA. Dormancy of metastatic melanoma. Pigment Cell Melanoma Res. 2010;23:41–56.
Flint ND, Bishop MD, Smart TC, et al. Low accuracy of self-reported family history of melanoma in high-risk patients. Fam Cancer. 2021;20:41–48.
Hedley JA, Kelly PJ, Waller KMJ, et al. Perceived versus verified cancer history and missed opportunities for donation in an Australian cohort of potential deceased solid organ donors. Transplant Direct. 2022;8:e1252.
Beuscart J-B, Pagniez D, Boulanger E, et al. Registration on the renal transplantation waiting list and mortality on dialysis: an analysis of the French REIN Registry using a multi-state model. J Epidemiol. 2015;25:133–141.
Klassen DK, Edwards LB, Stewart DE, et al. The OPTN deceased donor potential study: implications for policy and practice. Am J Transplant. 2016;16:1707–1714.
Rosales B, Hedley J, De La Mata N, et al.; SAFEBOD Study Group. Safety and Biovigilance in Organ Donation (SAFEBOD): protocol for a population-based cohort study. JMIR Res Protoc. 2020;9:e18282.
Thomson IK, Rosales BM, Kelly PJ, et al. Epidemiology and comorbidity burden of organ donor referrals in Australia: cohort study 2010-2015. Transplant Direct. 2019;5:e504.
NSW Ministry of Health. Public Health Act 2010 No 127. In: NSW Parliament, ed. No 127. 4 October 2022 to date ed2010.
Australian Consortium for Classification D. The International Statistical Classification of Diseases and Related Health Problems, tenth revision, Australian modification (ICD-10-AM/ACHI/ACS). Ninth ed. Darlinghurst, NSW: Independent Hospital Pricing Authority; 2015.
WHO Collaborating Centre on Vigilance and Surveillance for Human Cells Tissue and Organs. The NOTIFY booklet - Vigilance and Surveillance of Medical Products of Human Origin. Italy: Centro Nazionale Trapianti (Italian National Transplant Centre);2017.
The Transplantation Society of Australia and New Zealand. Clinical guidelines for organ transplantation from deceased donors. Canberra, Australia: The Transplantation Society of Australia and New Zealand; 2023.
The advisory committee on the Safety of Blood TaOS. Transplantation of organs from deceased donors with cancer or a history of cancer. In: Department of Health and Social Care, ed. SaBTO reports and guidance documents. UK: UK Governement; 2020.
Bajaj NS, Watt C, Hadjiliadis D, et al. Donor transmission of malignant melanoma in a lung transplant recipient 32 years after curative resection. Transpl Int. 2010;23:e26–e31.
Domínguez-Gil B, Moench K, Watson C, et al. Prevention and management of donor-transmitted cancer after liver transplantation: guidelines from the ILTS-SETH Consensus Conference. Transplantation. 2022;106:e12–e29.
Abdel-Wahab N, Safa H, Abudayyeh A, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J ImmunoTher Cancer. 2019;7:106.
Boyle SM, Ali N, Olszanski AJ, et al. Donor-derived metastatic melanoma and checkpoint inhibition. Transplant Proc. 2017;49:1551–1554.
Australia. CC. Skin cancer types. Cancer Council. Cancer Council Australia: Skin Cancer Statistics & Issues Web site. Available at https://wiki.cancer.org.au/skincancerstats/Skin_cancer_types#cite_note-Citation:American_Joint_Committee_on_Cancer_2017-19. Published 2023. Accessed July 18, 2023.
Australia. C. Melanoma of the skin. The Australian Government. Melanoma of the skin statistics Web site. Available at https://www.canceraustralia.gov.au/cancer-types/melanoma/statistics. Published 2023
Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941–1953.